TP53 and cancer: Absence of clinical data such as stage,tumor size, and histological grade may have hindered results interpretation.Cancer’s biological heterogeneity implies that prognostic factors like tumoraggressiveness and treatment response may have a direct impact on clinical outcomes.To address these limitations, we considered alternative variables to indirectlyreflect disease severity and progression, such as the number of chemotherapy,radiotherapy, and hormone therapy sessions, as well as tumor molecularcharacterization through biomarkers like HER2, Ki-67, and p53 mutation.